BioDlink(TOT BIOPHARM)

TOT BIOPHARM is a China-based startup that is dedicated to becoming the industry leading and trusted biopharmaceutical best partner for global clients. The company has extensive practical experience, mature technical platforms, and a robust quality system, which has enabled it to develop diversified strategic partnerships with domestic and international pharmaceutical companies. Their focus is to provide one-stop CDMO solutions for drug development and manufacturing, particularly in the field of biologics, including antibody-drug conjugates (ADCs). With a large-scale commercial GMP production base for biological drugs, TOT BIOPHARM has established itself as a key player in the industry, with a total manufacturing capacity exceeding 20,000 L. The company has also successfully built an integrated platform for ADCs, reducing transfer costs and regulatory risks. Moreover, they have a quality management system in line with commercial manufacturing, which has supported the commercial production of several marketed products. The last investment of $102.00M was in a Series B round on 08 August 2018, with participation from Chengwei Capital, Vivo Capital, Yuanta Financial Holdings Group, Cathay Capital, Center Ventures, 99Fund, GoldTech, and China Universal Asset Management. With a strong technological and commercial foundation, TOT BIOPHARM is well-positioned to continue its growth and impact within the biopharmaceutical industry.